Carcinogenic mechanism of incomplete cell reprogramming in vivo

Mar 14, 2014
Fig. 1 Mouse kidney subject to the action of reprogramming factors for 7 days Appearance of kidney exposed to four reprogramming factors for 7 days and then left for a further 7 days. Compared to the control kidney, the kidney exposed to the reprogramming factors has grown larger due to tumor formation. The right-hand image shows the histological stain pattern of a +Doxycyclin kidney. Scale bar: 200µm.

A research team led by the group of Professor Yasuhiro Yamada, Center for iPS Cell Research and Application (CiRA), Kyoto University, has discovered that when cells are subjected to incomplete reprogramming in vivo, epigenetic modifications take place which promote carcinogenesis.

iPS cells and have the common attribute of being capable of unlimited proliferation, but whereas cancer is thought to arise through a series of gene mutations, iPS cells are generated by reprogramming somatic cells, which need not involve any gene mutation.

However, when mouse cells were exposed in vivo to four reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc) in such a way as to cause incomplete reprogramming, a major change occurred in the DNA methylation pattern (epigenome), resulting in tumorigenesis in a range of tissues. Tumors arising in the kidney through this process were very similar to Wilms' tumor, a pediatric kidney cancer, in terms of histological and molecular biological features. An examination of the cells of these tumors revealed no gene mutation, but did identify modifications in the epigenome, which was found to have altered to a pattern resembling that of . Furthermore, the researchers were able to generate normal kidney cells from iPS cells created by reprogramming the tumor cells. These findings indicate the possibility that epigenetic regulation may promote tumorigenesis in certain types of cancer.

The findings of the research demonstrated that incomplete reprogramming using a procedure devised to reprogram in vivo leads to the formation of tumors resembling nephroblastoma. Previously it had been thought that cumulative gene mutations were important in oncogenesis. However, the results of the present research indicate that, with certain types of tumor, cancer can be triggered not by , but by epigenetic alterations. In other words, if it were possible to alter epigenetic conditions, it might be possible to alter the properties of cancer , which could lead in the future to new cancer therapies.

The present research additionally made use of iPS cell technology to develop a technique for epigenetic regulation that does not induce genomic mutation. It is hoped that using iPS cell technology in this way will bring new perspectives to disease research.

Explore further: New hope for stem cells, regenerative medicine emerges from the lab

More information: "Premature Termination of Reprogramming In Vivo Leads to Cancer Development through Altered Epigenetic Regulation." Kotaro Ohnishi, Katsunori Semi, Takuya Yamamoto, Masahito Shimizu, Akito Tanaka, Kanae Mitsunaga, Keisuke Okita, Kenji Osafune, Yuko Arioka, Toshiyuki Maeda, Hidenobu Soejima, Hisataka Moriwaki, Shinya Yamanaka, Knut Woltjen, Yasuhiro Yamada. Cell - 13 February 2014 (Vol. 156, Issue 4, pp. 663-677) dx.doi.org/10.1016/j.cell.2014.01.005

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

YEATS protein potential therapeutic target for cancer

Oct 23, 2014

Federal Express and UPS are no match for the human body when it comes to distribution. There exists in cancer biology an impressive packaging and delivery system that influences whether your body will develop cancer or not.

Precise and programmable biological circuits

Oct 23, 2014

A team led by ETH professor Yaakov Benenson has developed several new components for biological circuits. These components are key building blocks for constructing precisely functioning and programmable bio-computers.

User comments : 0